HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice
Journal Article
2010
Permanent link to this Item
Authors
Journal Title
Journal of Immune Based Therapies and Vaccines
Link to Journal
Journal ISSN
Volume Title
Publisher
BioMed Central Ltd
Publisher
University of Cape Town
Department
Faculty
Series
Abstract
Several approaches have been explored to eradicate HIV; however, a multigene vaccine appears to be the best option, given their proven potential to elicit broad, effective responses in animal models. The Pr55Gag protein is an excellent vaccine candidate in its own right, given that it can assemble into large, enveloped, virus-like particles (VLPs) which are highly immunogenic, and can moreover be used as a scaffold for the presentation of other large non-structural HIV antigens. In this study, we evaluated the potential of two novel chimaeric HIV-1 Pr55Gag-based VLP constructs - C-terminal fusions with reverse transcriptase and a Tat::Nef fusion protein, designated GagRT and GagTN respectively - to enhance a cellular response in mice when used as boost components in two types of heterologous prime-boost vaccine strategies. A vaccine regimen consisting of a DNA prime and chimaeric HIV-1 VLP boosts in mice induced strong, broad cellular immune responses at an optimum dose of 100 ng VLPs. The enhanced cellular responses induced by the DNA prime-VLP boost were two- to three-fold greater than two DNA vaccinations. Moreover, a mixture of GagRT and GagTN VLPs also boosted antigen-specific CD8+ and CD4+ T-cell responses, while VLP vaccinations only induced predominantly robust Gag CD4+ T-cell responses. The results demonstrate the promising potential of these chimaeric VLPs as vaccine candidates against HIV-1.
Description
Reference:
Pillay, S., Shephard, E. G., Meyers, A. E., Williamson, A. L., & Rybicki, E. P. (2010). HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice. Journal of immune based therapies and vaccines, 8(1), 7.